SEHK:2509Biotechs
Qyuns Therapeutics (SEHK:2509) Profitability Shift Challenges Bearish Earnings Narratives
Qyuns Therapeutics (SEHK:2509) has just posted its FY 2025 numbers, headlined by first half revenue of C¥206.5 million and a basic EPS loss of C¥0.13, while the latest trailing twelve month figures show revenue of C¥806.9 million and basic EPS of C¥1.41 as the business moved into profit over the period. Over the last three reported halves, revenue has stepped up from C¥44.9 million in 1H 2024 to C¥113.9 million in 2H 2024 and then to C¥206.5 million in 1H 2025, with net income swinging from...